Chantal Pichon

Dr. Chantal Pichon

Centre de Biophysique Moléculaire CNRS UPR 4301, rue Charles Sadron, Orléans 45071, France
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Current Opinion in Biotechnology
Verified
Journal Article
Closed access
Chantal PichonChantal Pichon
Chantal Pichon
LBLudivine Billiet
Ludivine Billiet
PMPatrick Midoux
Patrick Midoux

1 January 2017 in Mediators of Inflammation
Verified
Journal Article
Open access
FAFlorence ABDALLAH
Florence ABDALLAH
LMLily Mijouin
Lily Mijouin
Chantal PichonChantal Pichon
Chantal Pichon
The skin is an essential organ to the human body protecting it from external aggressions and pathogens. Over the years, the skin was proven to have a crucial immunological role, not only being a passive protective barrier but a network of effector cells and molecular mediators that constitute a highly sophisticated compound known as the “skin immune system” (SIS). Studies of skin immune sentinels provided essential insights of a complex and dynamic immunity, which was achieved through interaction between the external and internal cutaneous compartments. In fact, the skin surface is cohabited by microorganisms recognized as skin microbiota that live in complete harmony with the immune sentinels and contribute to the epithelial barrier reinforcement. However, under stress, the symbiotic relationship changes into a dysbiotic one resulting in skin disorders. Hence, the skin microbiota may have either positive or negative influence on the immune system. This review aims at providing basic background information on the cutaneous immune system from major cellular and molecular players and the impact of its microbiota on the well-coordinated immune responses in host defense.

26 August 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SUSatoshi Uchida
Satoshi Uchida
FPFédérico Perche
Fédérico Perche
Chantal PichonChantal Pichon
Chantal Pichon
Horacio CabralHoracio Cabral
Horacio Cabral

1 May 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
AMA. Le Moignic
A. Le Moignic
VMV. Malard
V. Malard
TBT. Benvegnu
T. Benvegnu
LLLoïc Lemiègre
Loïc Lemiègre
MBM. Berchel
M. Berchel
VMV. Mateo
V. Mateo

9 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FMFernanda C. Moraes
Fernanda C. Moraes
Chantal PichonChantal Pichon
Chantal Pichon
Didier LetourneurDidier Letourneur
Didier Letourneur
Frederic ChaubetFrederic Chaubet
Frederic Chaubet
MicroRNAs (miRNAs) are short (~21–23 nucleotides), non-coding endogenous RNA molecules that modulate gene expression at the post-transcriptional level via the endogenous RNA interference machinery of the cell. They have emerged as potential biopharmaceuticals candidates for the treatment of various diseases, including cancer, cardiovascular and metabolic diseases. However, in order to advance miRNAs therapeutics into clinical settings, their delivery remains a major challenge. Different types of vectors have been investigated to allow the delivery of miRNA in the diseased tissue. In particular, non-viral delivery systems have shown important advantages such as versatility, low cost, easy fabrication and low immunogenicity. Here, we present a general overview of the main types of non-viral vectors developed for miRNA delivery, with their advantages, limitations and future perspectives.

1 November 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
VVV. Vijayarangan
V. Vijayarangan
ADA. Delalande
A. Delalande
SDS. Dozias
S. Dozias
JPJ.-M. Pouvesle
J.-M. Pouvesle
ERERIC ROBERT
ERIC ROBERT
Chantal PichonChantal Pichon
Chantal Pichon